Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Leases: 2023-2025

Historic Current Leases for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $4.2 million.

  • Monte Rosa Therapeutics' Current Leases rose 16.32% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 16.32%. This contributed to the annual value of $3.7 million for FY2024, which is 17.46% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Current Leases stood at $4.2 million for Q3 2025, which was up 3.59% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Current Leases ranged from a high of $4.2 million in Q3 2025 and a low of $2.7 million during Q2 2023.
  • In the last 3 years, Monte Rosa Therapeutics' Current Leases had a median value of $3.5 million in 2024 and averaged $3.5 million.
  • Data for Monte Rosa Therapeutics' Current Leases shows a peak YoY skyrocketed of 30.15% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Current Leases (Quarterly) stood at $3.2 million in 2023, then rose by 17.46% to $3.7 million in 2024, then climbed by 16.32% to $4.2 million in 2025.
  • Its last three reported values are $4.2 million in Q3 2025, $4.1 million for Q2 2025, and $3.9 million during Q1 2025.